IVI released our initial version of the new Open-Source Value Platform (OSVP) model for non-small cell lung cancer. Specifically, the model provides information on the relative value of sequential treatments for epidermal growth factor receptor positive (EGFR+), non-squamous non-small cell lung cancer (NSCLC). The entirety of the IVI-NSCLC model package, including detailed methods documentation, R [...]
Los Angeles, CA – November 15, 2018 – The Innovation and Value Initiative (IVI) – a nonprofit dedicated to advancing the science and improving the practice of value assessment in healthcare – today released qualitative research evaluating what factors most impact the value of treatment to metastatic non-small cell lung cancer patients. According to the [...]
Los Angeles, CA – November 13, 2018 – The Innovation and Value Initiative (IVI) – a collaboration dedicated to advancing the science and improving the practice of value assessment in healthcare – will present research at this week’s ISPOR Europe 2018 conference showcasing different elements of the Open-Source Value Project (OSVP) initiative to facilitate assessment [...]
ISPOR Conference Examines How New Approaches to Value Assessment May Help Move Toward More Informed Pricing Washington, D.C. –- October 19, 2018 -- At the ISPOR Summit 2018, the lead scientific advisor for the Innovation and Value Initiative (IVI) - a collaboration dedicated to advancing the science and improving the practice of value assessment in [...]
IVI’s Executive Director Discusses Moving Beyond the Average in Value Assessment at Xtelligent Media’s Value Based Summit 2018 Boston, MA –- October 18, 2018 -- Value Assessment 2.0 requires building assessment models that account for all of the factors that determine value instead of focusing only on cost and clinical benefits, said the executive director [...]
Priorities Emerged Which Will Shape Version 2.0 of IVI’s RA Model Los Angeles, CA – September 20, 2018 -- The Innovation and Value Initiative (IVI) today released public feedback and recommendations from its Technical Expert Panel (TEP), an objective third party comprised of five leaders in health economics, epidemiology, rheumatology, and patient communities, which the [...]
IVI Says Moving Beyond Cost Effectiveness by Evaluating Treatments Based on Unique Patient Characteristics and Preferences is Imperative Los Angeles, CA – July 16, 2018 -- If we are going to truly harness data to lower healthcare costs while accelerating and rewarding innovation that benefits patients, then defining and assessing value in healthcare must [...]
Los Angeles, CA -- June 20, 2018 -- Oncology is both an area of immense clinical need and a primary driver of healthcare spending. As a result, cancer care is a focus of extensive debate around value. In short, the field of oncology offers a unique opportunity to develop patient-centered, robust, and flexible models [...]
Washington, D.C. -- June 14, 2018 -- Measuring value in healthcare, which traditionally takes the perspective of a single payer managing population health and costs, needs to evolve to include diverse perspectives and provide relevant and actionable information on value to healthcare decision makers, according to a new article published today in the Journal [...]
The Institute for Clinical Economic Review (ICER) recently launched a new pilot program that will allow more extensive evaluation of draft economic models used in ICER's reports. In response to ICER's new program, Mark Linthicum, Director of Scientific Communications for the Innovation and Value Initiative (IVI), commented: "The Innovation and Value Initiative (IVI) is working diligently [...]